(AOF) – Genomic Vision has announced the issue of a third tranche of bonds convertible into shares with share subscription warrants (Ocabsa) for a net amount of 1.92 million euros. This biotechnology company developing products and services for the precise characterization of DNA sequences recalls that it had announced the signing of an issuance contract on April 11, 2022 with Winance for a total maximum net amount of 28.8 million euros (30 million euros nominal value).
The company also confirms its intention to continue its investments in order to carry out its strategic plan and it will therefore soon draw a new tranche of financing by issuing 2,000,000 Ocabsa which will be subscribed by the investor subject to the fulfillment of the conditions set out in the financing program.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.